Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model.
Radiolabeled peptides are emerging tools for diagnosis and therapy of tumors overexpressing receptors. However, binding to receptors expressed by nontumor tissues may cause toxicity. The objective of this study was to specifically enhance the binding affinity of labeled peptides to tumor cells, as opposed to receptor-positive nontumor cells, to ensure targeting selectivity. This was achieved by the simultaneous binding of hapten-bearing peptides to their receptor and to a tumor-associated antigen, mediated by a bispecific antibody directed to the tumor antigen and to the hapten. Binding of labeled neurotensin analogues bearing the DTPA(indium) hapten (NT-DTPA(111In)) to human colorectal carcinoma cells (HT29), which express the neurotensin receptor (NTR1) and carcinoembryonic antigen (CEA), was studied in the presence of a bispecific antibody (BsmAb) directed to CEA and to DTPA(indium). In vitro dual binding of NT-DTPA in the presence of BsmAb was about 6.5-fold higher than monovalent binding to NTR1 and 3.5-fold higher than the sum of the monovalent bindings to NTR1 or to CEA, suggesting cooperativity. Increased binding under bivalent conditions translated into increased internalization. In vivo pretargeting with BsmAb enhanced tumor uptake and tumor retention. Hapten bearing peptides binding simultaneously an overexpressed cell-surface receptor and a tumor antigen show increased selectivity to target tumor cells as compared to cells only expressing the cell surface receptor. Better resistance to enzymatic degradation and optimized administration protocols should further enhance in vivo targeting selectivity and may allow the development of radiopharmaceuticals labeled with isotopes suitable for radiotherapy such as 131I or 90Y.
Hillairet De Boisferon
Marc
M
INSERM U339, Faculté de Médecine et Hôpital Saint-Antoine, Paris, France.
Raguin
Olivier
O
Thiercelin
Cynthia
C
Dussaillant
Monique
M
Rostène
William
W
Barbet
Jacques
J
Pélegrin
André
A
Gruaz-Guyon
Anne
A
D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000378:metabolism; D003198:Computer Simulation; D005260:Female; D006241:Haptens / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D007700:Kinetics; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D004369:Pentetic Acid / Q000737:chemistry / Q000493:pharmacokinetics; D010446:Peptide Fragments / Q000276:immunology / Q000627:therapeutic use; D016719:Radioimmunodetection; D016499:Radioimmunotherapy; D018028:Receptors, Neurotensin / Q000378:metabolism*; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured
D018033:Antibodies, Bispecific; D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; D006241:Haptens; D007205:Indium Radioisotopes; D010446:Peptide Fragments; D018028:Receptors, Neurotensin; C114036:neurotensin type 1 receptor; D004369:Pentetic Acid